Latest news

• AbbVie lauds head-to-head win for Skyrizi versus Cosentyx

  On paper Skyrizi is actually a closer competitor to Johnson &Johnson's Tremfya (guselkumab), which also targets IL-23, but there’s little doubt that – sales-wise at least – Cosentyx is ... Tremfya, which made $742m for J&J in the first nine months

• J&J splashes $750m on anti-inflammatory drug bermekimab

  J&J already has high stakes in the anti-inflammatory market, with its blockbuster IL-12/IL-23 inhibitor blockbuster Stelara (ustekinumab) and follow-up Tremfya (guselkumab). ... loss. If it can win approval, Tremfya will become the first selective IL-23

• Novartis’ Cosentyx misses the mark in Humira head-to-head

  This includes Johnson &Johnson’s Tremfya (guselkumab), AbbVie’s Skyrizi (risankizumab), Eli Lilly’s Taltz (ixekizumab) and Pfizer’s Xeljanz (tofacitinib citrate).

• Janssen files Tremfya for psoriatic arthritis in Europe

  If approved by the EMA, Tremfya will be the first selective IL-23 inhibitor for people with active PsA in the EU. ... Some analysts suggest Skyrizi matches Tremfya for efficacy but offers less frequent dosing during the maintenance phase of treatment, as

• Litigation concerns threaten to overshadow solid quarter at J&J

  Growth for immunology therapy Stelara (ustekinumab) and blood cancer drugs Imbruvica (ibrutinib) and Darzalex (daratumumab) – plus Stelara follow-up Tremfya (guselkumab) – outweighed the effect of generic competition to older prostate cancer